Sequenta Earns CLIA Certification

Published: Oct 24, 2012

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. today announced it has received Clinical Laboratory Improvement Amendments (CLIA) certification for a clinical test based on the LymphoSIGHT™ platform, marking a critical milestone for the clinical use of this next generation sequencing method for the monitoring of blood cancers. Sequenta expects to launch its first commercial test in 2013.

Back to news